MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.
Company profile
Ticker
MXCT
Exchange
Website
CEO
Douglas Doerfler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
Former names
MAXCYTE INC
SEC CIK
Corporate docs
Subsidiaries
CCTI, Inc. ...
IRS number
522210438
MXCT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
12 Mar 24
8-K
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
12 Mar 24
8-K
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
5 Mar 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
8 Jan 24
8-K
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
11 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
8 Nov 23
8-K
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
4 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
MXCT
Earnings call transcript
2023 Q3
8 Nov 23
MXCT
Earnings call transcript
2023 Q2
9 Aug 23
MXCT
Earnings call transcript
2023 Q1
10 May 23
MXCT
Earnings call transcript
2022 Q4
15 Mar 23
MXCT
Earnings call transcript
2022 Q3
12 Nov 22
MXCT
Earnings call transcript
2022 Q2
11 Aug 22
MXCT
Earnings call transcript
2022 Q1
10 May 22
MXCT
Earnings call transcript
2021 Q4
23 Mar 22
MXCT
Earnings call transcript
2021 Q3
13 Nov 21
MXCT
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
John Joseph Johnston
28 Mar 24
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
25 Mar 24
4
Thomas M. Ross
19 Mar 24
4
David I. Sandoval
19 Mar 24
4
Douglas J Swirsky
19 Mar 24
3
David I. Sandoval
4 Mar 24
4
John Joseph Johnston
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
SC 13G/A
Casdin Capital, LLC
14 Feb 24
SC 13G
CADIAN CAPITAL MANAGEMENT, LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 49.17 mm | 49.17 mm | 49.17 mm | 49.17 mm | 49.17 mm | 49.17 mm |
Cash burn (monthly) | 1.80 mm | (no burn) | 4.65 mm | 3.91 mm | 2.75 mm | 2.40 mm |
Cash used (since last report) | 12.33 mm | n/a | 31.94 mm | 26.87 mm | 18.86 mm | 16.45 mm |
Cash remaining | 36.84 mm | n/a | 17.23 mm | 22.30 mm | 30.31 mm | 32.72 mm |
Runway (months of cash) | 20.5 | n/a | 3.7 | 5.7 | 11.0 | 13.7 |
Institutional ownership, Q3 2023
64.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 120 |
Opened positions | 17 |
Closed positions | 13 |
Increased positions | 42 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 193.51 bn |
Total shares | 67.36 mm |
Total puts | 9.30 k |
Total calls | 900.00 |
Total put/call ratio | 10.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.89 mm | $21.49 bn |
Vitruvian Partners | 5.04 mm | $15.74 bn |
Vanguard | 5.04 mm | $15.72 bn |
Sofinnova Crossover I | 4.61 mm | $0.00 |
Millennium Management | 3.85 mm | $12.00 bn |
Stonepine Capital Management | 3.76 mm | $11.74 bn |
ArrowMark Colorado | 2.41 mm | $7.52 bn |
Portolan Capital Management | 2.14 mm | $6.69 bn |
Holocene Advisors | 2.12 mm | $6.61 bn |
Granahan Investment Management | 1.98 mm | $6.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | John Joseph Johnston | Common Stock | Sell | Dispose S | No | Yes | 4.405 | 5,000 | 22.03 k | 120,583 |
26 Mar 24 | John Joseph Johnston | Common Stock | Option exercise | Acquire M | No | Yes | 2.142 | 5,000 | 10.71 k | 125,583 |
26 Mar 24 | John Joseph Johnston | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.142 | 5,000 | 10.71 k | 617 |
15 Mar 24 | Thomas M. Ross | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
15 Mar 24 | Thomas M. Ross | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.31 | 100,000 | 431.00 k | 100,000 |
15 Mar 24 | Swirsky Douglas J | Common Stock | Grant | Acquire A | No | No | 0 | 81,250 | 0.00 | 81,250 |
15 Mar 24 | Swirsky Douglas J | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.31 | 225,000 | 969.75 k | 225,000 |
15 Mar 24 | David I. Sandoval | Common Stock | Grant | Acquire A | No | No | 0 | 3,913 | 0.00 | 45,913 |
15 Mar 24 | David I. Sandoval | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.31 | 15,625 | 67.34 k | 15,625 |
26 Feb 24 | John Joseph Johnston | Common Stock | Sell | Dispose S | No | Yes | 4.601 | 5,000 | 23.01 k | 120,583 |
News
Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $11 Price Target
23 Apr 24
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
20 Mar 24
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
20 Mar 24
Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $11 Price Target
13 Mar 24
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
13 Mar 24
Press releases
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
10 Apr 24
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
4 Apr 24
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
2 Apr 24
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
4 Mar 24
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
9 Feb 24